Palatin Technologies Inc (LTS:0KF3)
$ 1.1216 0.0122 (1.1%) Market Cap: 22.48 Mil Enterprise Value: 20.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Palatin Technologies Inc To Host Key Opinion Leader Webinar Transcript

Mar 07, 2022 / 03:30PM GMT
Release Date Price: $10.2
Operator

Good morning, and welcome to the Palatin Technologies KOL webinar on dry eye disease. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Palatin website following the conclusion of the event.

I'd now like to turn the call over to your host, Carl Spana, Chief Executive Officer of Palatin Technologies. Please go ahead, Carl.

Carl Spana
Palatin Technologies, Inc. - Co-Founder, President, CEO & Director

Thank you, Sara. Good morning, and welcome, everyone, to the Palatin Dry Eye Disease webinar.

We've designed a very nice seminar today. We have Dr. Eric D. Donnenfeld, who will start with covering what dry disease is, how he manages it, current treatments for dry eye disease and the unmet medical need, and some of the recently approved treatments. We'll follow it up with Dr. Michael Raizman, who will cover treatments in development and then we will focus on PL9643, Palatin's melanocortin agonist, which is in Phase III development as a treating -- for treating dry eye disease, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot